GlassScriptPhysician profile
Rene E Darveaux
NPI 1205866696
$9,026.66
in general payments reported to CMS, 2019-2025
46 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $585 · 2021: $478 · 2022: $2,059 · 2023: $1,723 · 2024: $1,460 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,560.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $813.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $790.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $774.84 | 2021-2025 | Vraylar, Qulipta |
| Amgen INC. | $604.71 | 2019-2025 | Krystexxa |
| Lilly USA, LLC | $561.86 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $498.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $402.14 | 2019-2022 | |
| Esperion Therapeutics, INC. | $342.52 | 2020-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $332.22 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $271.51 | 2019-2023 | |
| Dexcom, INC. | $221.60 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.04 | 2019-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $133.35 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.77 | 2020-2025 | Xifaxan, Trulance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Darveaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.